Summary
OMICSENS aims to develop a radically new omics measurement platform that would be initially applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase Inhibitor (TKI) resistance associated to Epidermal Growth Factor Receptor (EGFR) mutations. Subsequently, OMICSENS will be used to improve prognosis of patients suffering from other types of cancers.
OMICSENS targets the creation of the first nano-photonic integrated omics bio-sensor to tackle TKI resistance and improve NSCLC treatment outcome and patient prognosis. Thanks to OMICSENS, we will build a six layers technology comprised of an on-chip embedded infra-red source arrays, an artificial intelligence optimized nano-structured surface for photonic signal enhancement, a functionalized surface of high absorbance to specific analytes, a microfluidics system to deliver the sample, a metamaterial-based photo detector array with optimized quantum efficiency and an AI algorithm enabling analyte quantification. Our miniaturized omics bio-sensor will enable real time and concurrent measurements of omics, compatible with organ-on-chip (OOC) in the future. OOC is one of the most promising bioengineering developments, paving the way to more efficient drug testing and personalized medicine trough digital twinning of a biological system. But OOC is lacking a real-time, integrated bio-sensing technology. OMICSENS proposes a disruptive bio-sensor to bridge this gap. OMICSENS will create a radically new device useful for telehealth, capable of improving medical diagnostics, while fostering a patient-centered approach. To achieve our novel and ambitious objective, we have brought together an interdisciplinary consortium of top-level academics (LMU, UNITN, IBEC, KTH) and SMEs (MW, QAI, 4K-MEMS), including expertise in oncology, bio-engineering, micro-fluidics, biochemistry, MEMS, nano-photonics, computational physics and artificial intelligence.
OMICSENS targets the creation of the first nano-photonic integrated omics bio-sensor to tackle TKI resistance and improve NSCLC treatment outcome and patient prognosis. Thanks to OMICSENS, we will build a six layers technology comprised of an on-chip embedded infra-red source arrays, an artificial intelligence optimized nano-structured surface for photonic signal enhancement, a functionalized surface of high absorbance to specific analytes, a microfluidics system to deliver the sample, a metamaterial-based photo detector array with optimized quantum efficiency and an AI algorithm enabling analyte quantification. Our miniaturized omics bio-sensor will enable real time and concurrent measurements of omics, compatible with organ-on-chip (OOC) in the future. OOC is one of the most promising bioengineering developments, paving the way to more efficient drug testing and personalized medicine trough digital twinning of a biological system. But OOC is lacking a real-time, integrated bio-sensing technology. OMICSENS proposes a disruptive bio-sensor to bridge this gap. OMICSENS will create a radically new device useful for telehealth, capable of improving medical diagnostics, while fostering a patient-centered approach. To achieve our novel and ambitious objective, we have brought together an interdisciplinary consortium of top-level academics (LMU, UNITN, IBEC, KTH) and SMEs (MW, QAI, 4K-MEMS), including expertise in oncology, bio-engineering, micro-fluidics, biochemistry, MEMS, nano-photonics, computational physics and artificial intelligence.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101129734 |
| Start date: | 01-01-2024 |
| End date: | 31-12-2026 |
| Total budget - Public funding: | 2 372 318,75 Euro - 2 372 318,00 Euro |
Cordis data
Original description
OMICSENS aims to develop a radically new omics measurement platform that would be initially applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase Inhibitor (TKI) resistance associated to Epidermal Growth Factor Receptor (EGFR) mutations. Subsequently, OMICSENS will be used to improve prognosis of patients suffering from other types of cancers.OMICSENS targets the creation of the first nano-photonic integrated omics bio-sensor to tackle TKI resistance and improve NSCLC treatment outcome and patient prognosis. Thanks to OMICSENS, we will build a six layers technology comprised of an on-chip embedded infra-red source arrays, an artificial intelligence optimized nano-structured surface for photonic signal enhancement, a functionalized surface of high absorbance to specific analytes, a microfluidics system to deliver the sample, a metamaterial-based photo detector array with optimized quantum efficiency and an AI algorithm enabling analyte quantification. Our miniaturized omics bio-sensor will enable real time and concurrent measurements of omics, compatible with organ-on-chip (OOC) in the future. OOC is one of the most promising bioengineering developments, paving the way to more efficient drug testing and personalized medicine trough digital twinning of a biological system. But OOC is lacking a real-time, integrated bio-sensing technology. OMICSENS proposes a disruptive bio-sensor to bridge this gap. OMICSENS will create a radically new device useful for telehealth, capable of improving medical diagnostics, while fostering a patient-centered approach. To achieve our novel and ambitious objective, we have brought together an interdisciplinary consortium of top-level academics (LMU, UNITN, IBEC, KTH) and SMEs (MW, QAI, 4K-MEMS), including expertise in oncology, bio-engineering, micro-fluidics, biochemistry, MEMS, nano-photonics, computational physics and artificial intelligence.
Status
SIGNEDCall topic
HORIZON-EIC-2023-PATHFINDEROPEN-01-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
